HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the South Central Section of the American Urological Association Meeting in San Diego in September. The paper is authored by leading clinical research investigators participating in the U.S. clinical trials of NX-1207.
